Case report

Pulmonary epidermoid carcinoma in a patient with acromegaly: a rare entity

Siham El Aziz1, Asma Chadli1, Atika Ombiba1, Hassan El Ghomari1, Ahmed Farouqi1

1Department of endocrinology, diabetes and metabolism, Ibn Rochd University hospital, Casablanca, Morocco

&Corresponding author: Dr El Aziz Siham, DR S. El Aziz, Ibn Rochd Hospital, service d’Endocrinologie (p26), Quartier des hopitaux, Casablanca, Maroc

Key words: Acromegaly, carcinoma, pulmonary neoplasia, pituitary adenoma, epidermoid carcinoma

Received: 09/02/2012 - Accepted: 04/05/2012 - Published: 10/06/2012

Abstract

A 56-years-old woman was referred to our unit for partially treated acromegaly. She had a high level of insulin growth factor. She did not complain of any pulmonary symptoms and was a non-smoker. Physical examination revealed clinical features of acromegaly. She had a 13 mm pituitary adenoma and was proposed for surgical intervention. Her chest X-ray showed a right para-cardiac tumor. Computed tomography scan revealed a large right-sided Fowler tumor. Pituitary surgery was cancelled and lobectomy after biopsy with lymph nodes excision was performed through thoracotomy. Histological study of the tumor revealed a medium differentiated epidermoid carcinoma with positive lymph nodes and extension to pleura. She was referred to chemotherapy protocol. Association between carcinoma and acromegaly has previously been reported. Most common tumors are colorectal and thyroid neoplasia. As we see in this case report, we need to consider other carcinomas in acromegalic patients like pulmonary carcinoma, despite their rarity in women.
Introduction

Acromegaly is a chronic disease caused usually by a pituitary adenoma secreting excess growth hormone (GH). Untreated acromegaly is associated with a high morbidity and two-fold mortality risk [1,2]. Acromegalic patients have most frequently respiratory and vascular diseases [3]. More recently, many studies have shown an increase risk of neoplasias [4,5] in acromegalic patients [6,7], correlated to increase level of Insulin-like Growth Factor (IGF) and elevated proliferative activity [8-10]. The most common tumors are colorectal neoplasias, breast and thyroid cancer [11-13]. Screening of tumors must be done before and after transphenoidal surgery, and long term follow up is needed in partially treated acromegalic patients. Pulmonary carcinomas are much rare than other carcinoma in non-smoking acromegalic patients. We report a case of epidermoid carcinoma in an acromegalic woman and discuss this rare association.

Patient and observation

We report the case of a 56-years-old non-smoking female patient diagnosed with acromegaly seven years ago and treated by transphenoidal surgery and radiotherapy. She was referred to our unit for persistent acromegaly. She had evident signs of acromegaly on clinical examination. Laboratory investigation demonstrated increase IGF1 at 429 ng/ml and pituitary 13 mm macro-adenoma. She didn’t have metabolic complications. Our decision was surgery, because of non availability of medical treatment. She was referred to the neurosurgeon and proposed a trans-sphenoidal adenoma removal. A routine chest-X-ray, done in the pre-operative workout, revealed a right sided paracardiac opacity (Figure 1). A thorax computed tomography scan (CT) showed a large tumor of the right medium lobe, in contact with the big lung sulcus and an enlargement of the right inferior lobe (Figure 2 and Figure 3). Abdominal CT was undertaken before surgery to exclude other localisations. Biopsy through thoracotomy revealed a malignant tumor. Resection of the right inferior pulmonary lobe with mediastinal lymph nodes excision were realized. Histological examination demonstrated a 5 cm epidermoid carcinoma poorly differentiated with extension to pleura and with metastatic lymphnodes. Pituitary surgery was cancelled; the patient was referred to an oncological center for chemotherapy protocol.

Discussion

Acromegaly is a rare disease with a prevalence of 40 cases/1 million population and 3 new cases/1 million population per year due to excess growth hormone (GH) secreted usually by a pituitary adenoma [14,15]. Majority of clinical and metabolic complications of acromegaly are caused by increase levels of GH which induce high insulin like growth factor 1 (IGF1) [16]. Beside morbidity of acromegaly, mortality seems to be increased in this disease. Several studies concerning long term follow-up of acromegalic patients demonstrated a link between acromegaly and cancer since IGF1 increase proliferative activity of cells [17,18]. Most common tumors are colorectal [19], thyroid carcinoma [20], breast and prostate tumors. It is recommended for acromegalic patients to undergo screening colonoscopy and thyroid ultrasonography [11]. Great attention had been provided to colorectal cancer since a high level of IGF1 has been correlated to increase risk of colorectal cancer [9,21-23]. The American Cancer Society defined acromegalic patients just above the average risk of colorectal cancer [24] and recommend that colonoscopy should be prescribed after the age of 50 [25].

Lung cancer is the most frequent cancer inducing deaths in women and men according to the American Cancer Society [24]. Lung cancer in acromegalic patients seems to be rare; and it’s seems like there is not an increase prevalence of non-small cell cancer in acromegalic patients compared to normal population according to several studies [5,17,26] even if high level of IGF1 value increase proliferation of lung cells [27,28]. Table 1 show the prevalence of most frequent cancer in acromegalic patients according to different studies. As we can see, neoplasias are frequent in acromegalic patients with a prevalence of about 10% according to these large scale epidemiological studies (Table 1). Lung carcinoma seems extremely rare in patients with acromegaly. Our female patient was a non-smoking patient, she didn’t complain of chest pain, cough, trouble breathing or weight. The major risk factor for this patient seems to be the chronic exposure to high level of IGF1 resulting from partially treated acromegaly. Epidermoid carcinoma is a non-small lung cancer with small chance of recovery and poor prognosis when the cancer is in an advanced stage or in poorly-differentiated tumors, like in our patient. Since lung cancer may not be associated with any symptoms, a routine chest X-ray should be done for screening in acromegalic patient, including in treated patient with persistent high level of IGF1 [28].

Conclusion

Active disease may precede for several years the diagnosis of acromegaly because of indolence. HighI levels of IGF1 contribute to progression of malignant tumors. In acromegalic patients, screening is fundamental, and chest X-ray with CT may be necessary. During follow-up, more attention should be given in partially treated acromegalic patients because of persistent increase of IGF1 levels. Screening of neoplasias should be done in these high risk patients.

Competing interests

The authors declare no competing interests.

Tables and figures

Table 1: Cancer prevalence in acromegaly according to several studies
Figure 1: Right sided paracardiac opacity at chest X-ray without pleural effusion

Figure 2: Right medium lobe large tumor at the thorax tomography scan, with speculated margin, in contact with the big lung sulcus and enlargement of right inferior lobe

Figure 3: CT scan right ovalar 45x35 mm necrosed tumor with irregular margin, with no mediastinal lymph nodes, and no left parenchymatous anomaly and no pleural reaction

References

1. Ayuk John, Sheppard Michael C. Does acromegaly enhance mortality?. Rev Endocr Metab Disord. 2008; 9: 33-39. This article on PubMed

2. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004 Oct;151(4):439-46. This article on PubMed

3. Brada M, Ashley S, Ford D, Traish D, Burchell L, Rajan B. Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol (Oxf). 2002 Dec;57(6):713-7. This article on PubMed

4. Kauppinen-Mäkelin R, Sane T, Välimäki MJ, Markkanen H, et al. Increased cancer incidence in acromegaly - a nationwide survey. Clin Endocrinol (Oxf). 2010 Feb;72(2):278-9. This article on PubMed

5. Orme Stephen M, Mcnally Richard JQ, Cartwright Ray A et al. Mortality and Cancer Incidence in acromegaly: A retrospective Cohort Study - United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998; 83: 2730-2734. This article on PubMed

6. Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, et al. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxf). 1998 Oct;49(4):441-5. This article on PubMed

7. Baldys-Waligórska A, Krzentowska A, Golkowski F, et al. The prevalence of benign and malignant neoplasms in acromegalic patients. Endokrynol Pol. 2010 Jan-Feb;61(1):29-34. This article on PubMed

8. Yamaguchi M, Tate G, Yoshizawa Y, Midorikawa T, Sanada Y, Kumada K. Hepatocellular carcinoma in a patient with acromegaly and high serum levels of insulin-like growth factor I: report of a case. Surg Today. 2002;32(11):1008-11. This article on PubMed

9. Jenkins PJ, Frajese V, Jones AM, Camacho-Hubner C, et al. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab. 2000 Sep;85(9):3218-21. This article on PubMed

10. Loeper S, Ezzat S. Acromegaly: re-thinking the cancer risk. Rev Endocr Metab Disord. 2008 Mar;9(1):41-58. This article on PubMed

11. Dworakowska Dorota, Gueorguiev Maria, Kelly Paul, Monson John P, Besser G Michael, Chew Shern L et al. Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. European Journal of Endocrinology. 2010; 163: 21-28. This article on PubMed

12. Higuchi Yoshinori, Saeki Noakatsu, Iuchi Toshihiko, Uchino Yoshio, Tatsuno Ichiro, Uchida Daigaku, Tanaka Tomoaki et al. Incidence of Malignant Tumors in Patients with Acromegaly. Endocrine Journal. 2000; 47(Suppl): S57-S60. This article on PubMed

13. Tita P, Ambrosio Maria Rosaria, Scollo Claudia et al. High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol (Oxf). 2005; 63: 161-167. This article on PubMed

14. Norberg Lars, Johansson Robert and Rasmuson Torjgry. Pituitary adenomas in northern Sweden: a study on therapy choices and the risk of second primary tumours. Clinical Endocrinology. 2008; 68: 780-785. This article on PubMed

15. Scacchi Massimo, Cavagnini Francesca. Acromegaly. Pituitary. 2006; 9: 297-303. This article on PubMed

16. Miraki-Miloud Farideh, Jenkins Paul J, Fairclough Peter D, Jordan Stefan, Bustin Stefan A, Jones Angela M et al. Increased levels of insulin-like-growth-factor binding protein 2 in sera and tumors from patients with colonic neoplasias with and without acromegaly. Clinical endocrinology. 2001; 54: 499-508. This article on PubMed

17. Barris Daslu, Gridley Gloria, Ron Efrat et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes and Control. 2002; 13: 395-400. This article on PubMed

18. Barzilay Joshua, Heatley Gerald J, Cushing Gary W. Benign and Malignant Tumors in Patients With Acromegaly. Arch Intern Med. 1991; 151: 1629-1632. This article on PubMed
19. Kuromoto Makiko, Fukuda Izumi, Hizuka Naomi, Takano Kazue. The prevalence of benign and malignant tumors at a single institute. Endocrine Journal. 2008; 55(1): 67-71. [This article on PubMed]

20. Gasperi Marianna, Martino Elena, Manetti Luca, Arosio Massimo, Porretti Silvia, Faglia Giovanni et al, Acromegaly Study Group of the Italian Society of Endocrinology. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest. 2002; 25(3): 240-5. [This article on PubMed]

21. Manousos Orestis, Souglakos John, Bosetti Cristina et al. IGF-I and IGFII in relation to colorectal cancer. Int J Cancer. 1999; 83: 15-17. [This article on PubMed]

22. Ma J, Pollak M, Giovannucci E, Chan JM, Tao Y, Hennekens C, Stampfer MJ. A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth Horm IGF Res. 2000 Apr;10 Suppl A:S28-9. [This article on PubMed]

23. Giovannucci Edward, Pollak Michael N, Platz Elizabeth A et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 Acromegaly and risk of cancer 399 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev. 2000; 9: 345-349. [This article on PubMed]

24. American Cancer Society. Cancer reference information. Atlanta: American Cancer Society 2007

25. Renehan AG, Brennan BM. Acromegaly, growth hormone and cancer risk. Best Pract Res Clin Endocrinol Metab. 2008 Aug;22(4):639-57. [This article on PubMed]

26. Ron Efrat, Gridley Gloria, Hrubec Zdenec et al. Acromegaly and gastrointestinal cancer. Cancer. 1991; 68: 1673-1777. [This article on PubMed]

27. Jaques Gabrielle, Rotsch Martin, Wegmann Carole et al. Production of immunoreactive insulin-like growth factor 1 and response to exogenous IGF-1 in small cell lung cancer lines. Exp Cell Res. 1988; 176: 336-343. [This article on PubMed]

28. Rotsch M, Maasberg M, Erbil C, et al. Characterization of insulin-like growth factor I receptors and growth effects in human lung cancer cell lines. J Cancer Res Clin Oncol. 1992;118(7):502-8. [This article on PubMed]
| Variables                        | Baris [17] | Popovic [6] | Baldys-Waligorska [7] | Barzilay [18] | Orme [5] |
|---------------------------------|------------|-------------|------------------------|---------------|---------|
| Year of study                   | 2001       | 1997        | 2010                   | 1991          | 1998    |
| Number of patients with acromegaly | 1634      | 220         | 101                    | 87            | 1362    |
| Medium age at diagnosis (years) | 50.4       | 49.5 ± 0.9  | 51.8 ± 15.4            | 37            | -       |
| Mean follow-up (years)          | 10.3       | 4.5 ± 0.4   | 9.4 ± 6.5              | 13            | -       |
| **Number of cancer**            |            |             |                        |               |         |
| n                               | 177        | 23          | 12                     | 7             | 79      |
| %                               | 10.8       | 10.4        | 11.8                   | 8             | 5.8     |
| **Malignancy localisation (n)** |            |             |                        |               |         |
| Colorectal                      | 34         | 2           | 2                      | 1             | 16      |
| Thyroid                         | 3          | 3           | 3                      | 2             | 1       |
| Breast                          | 20         | 4           | 1                      | 1             | 14      |
| Cervix                          | 3          | 4           | 3                      | 0             | -       |
| Endometor                       | 4          | 0           | 0                      | 0             | -       |
| Bladder                         | 3          | 1           | 0                      | 0             | -       |
| Stomach                         | 6          | 0           | 1                      | 0             | -       |
| Kidney                          | 12         | 1           | 0                      | 0             | -       |
| Lung                            | 14         | 0           | 1                      | 0             | -       |
| Ovary                           | 2          | 1           | 0                      | 1             | 6       |
| Hematopoietic                   | 23         | 3           | 0                      | 1             | -       |
| Skin                            | 13         | 2           | 0                      | 1             | -       |
| Prostate                        | 13         | 0           | 1                      | 0             | -       |
| Brain                           | 9          | 0           | 0                      | 0             | -       |
| Bone                            | 2          | 0           | 0                      | 0             | -       |
| Other digestive                 | 16         | 2           | 0                      | 0             | -       |
Figure 1
Right sided paracardiac opacity at chest X-ray without pleural effusion
Figure 2

Right upper lobe large tumor at the thoracic tomography scan, with speculated margins, in contact with the big lung sulcus and enlargement of right inferior lobe.
Figure 3
CT scan right oval 45x35 mm necrosed tumor with irregular margin, with no mediastinal lymph nodes, and no left parenchymatous anomaly and no pleural reaction.